ClinicalTrials.Veeva

Menu
C

ClinSearch, LLC | Chattanooga, TN

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Relamorelin
GED-0301
Lactulose
Galcanezumab
ABP-671
SPD476
Emricasan
crofelemer
Plecanatide
AK002

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 87 total trials

A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (ARNASA)

This study will evaluate the efficacy and safety of astegolimab compared with placebo in participants with chronic obstructive pulmonary disease (COP...

Enrolling
Chronic Obstructive Pulmonary Disease (COPD)
Drug: Astegolimab
Drug: Placebo

The primary objectives of this study are to assess the safety, tolerability, and efficacy of ABP-671 in lowering serum uric acid (sUA) in participant...

Invitation-only
Gout
Drug: Allopurinol
Drug: ABP-671

A phase 2b, multicenter, randomized, double-blind, placebo-controlled study of HTD1801 in adult subjects with non-alcoholic steatohepatitis and liver...

Active, not recruiting
Nonalcoholic Steatohepatitis (NASH)
Type 2 Diabetes
Drug: Placebo
Drug: HTD1801

Cenobamate (YKP3089) is a small molecule approved in the United States (US), Europe and several other countries around the world for the treatment of...

Enrolling
Focal Onset Seizure
Drug: Cenobamate

This is a multicenter, randomized, double-blind, Phase 2b/3 study to evaluate the efficacy and safety of ABP-671. Part 1 of the study will compare th...

Active, not recruiting
Gout
Other: Placebo
Drug: Allopurinol

This is an open-label extension of the parent studies AROAPOC3-2001 and AROAPOC3-2002. Adult participants with dyslipidemia who completed the blinded...

Active, not recruiting
Dyslipidemias
Drug: ARO-APOC3

This study is a phase 2 study to Evaluate Efficacy, Safety and Tolerability of HM15211 Treatment for 12 Months in Subjects with Biopsy Confirmed NASH

Enrolling
NASH - Nonalcoholic Steatohepatitis
Drug: HM15211
Drug: Placebo of HM15211

Trial sponsors

Allergan logo
Bausch Health logo
Lilly logo
Celgene logo
Ferring logo
Shire logo
Pfizer logo
A
A
Bayer logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems